Skip to main content
Evidence Snapshot

Prostaglandin D2 receptor 2

CHEMBL5071 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5071
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin D2 receptor 2 as ChEMBL target CHEMBL5071, mapped to UniProt Q9Y5Y4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin D2 receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5071
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y5Y4
Prostaglandin D2 receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prostaglandin D2 receptor 2 matters

As of 2026-09-13

Prostaglandin D2 receptor 2 is reviewed as Prostaglandin D2 receptor 2 (UniProt Q9Y5Y4); Prostaglandin D2 receptor 2 shows late clinical disease relevance led by asthma. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 3584 compounds, and 284 assays, with lead potency reaching pChEMBL 10.9.

Disease context
asthma

Prostaglandin D2 receptor 2 shows late clinical disease relevance led by asthma. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ADC3680, ARRY-502, AZD1981.

Start review with asthma because it currently carries late clinical support. Linked drugs include ADC3680, ARRY-502, AZD1981, BI-671800. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 11 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 3584 compounds, and 284 assays for this target. The dominant activity type is IC50. CHEMBL1088284 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL1088284 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prostaglandin D2 receptor 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y5Y4, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why asthma is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3584
Total Compounds
284
Total Assays
5
Approved Drugs
IC50: 3024.0, KI: 1586.0, EC50: 277.0, KD: 5.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1088284
 10.9 IC50 —
No preferred name
CHEMBL2181748
 10.7 IC50 —
No preferred name
CHEMBL1081033
 10.1 IC50 —
No preferred name
CHEMBL1087029
 10.1 IC50 —
No preferred name
CHEMBL1087622
 10.1 IC50 —

Approved Drugs

Structure Compound First Approval
RAMATROBAN
CHEMBL361812
 2000
INDOMETHACIN
CHEMBL6
 1965
LAROPIPRANT
CHEMBL426559
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5071